Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD. Zeidan AM, et al. Among authors: smith mr. Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4. Br J Haematol. 2014. PMID: 24995683 Free PMC article.
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Tallman MS, Gore SD; Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup. Zeidan AM, et al. Among authors: smith mr. Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9. Br J Haematol. 2014. PMID: 24712482 Free PMC article.
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Figueroa M, Gabrilove J, Erba HP, Tallman MS, Litzow M, Gore SD; Eastern Cooperative Oncology Group and North American Leukemia intergroup. Prebet T, et al. Among authors: smith mr. Br J Haematol. 2016 Feb;172(3):384-91. doi: 10.1111/bjh.13832. Epub 2015 Nov 18. Br J Haematol. 2016. PMID: 26577691 Free PMC article. Clinical Trial.
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS. Prebet T, et al. Among authors: smith mr. J Clin Oncol. 2014 Apr 20;32(12):1242-8. doi: 10.1200/JCO.2013.50.3102. Epub 2014 Mar 24. J Clin Oncol. 2014. PMID: 24663049 Free PMC article. Clinical Trial.
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP. Martin P, et al. Among authors: smith mr. Br J Haematol. 2017 Jul;178(2):250-256. doi: 10.1111/bjh.14667. Epub 2017 Apr 17. Br J Haematol. 2017. PMID: 28419413 Free PMC article.
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC, Hussein MA, Appelbaum FR, Larson RA, Litzow MR, Tallman MS. Smith MR, et al. Blood. 2011 Sep 29;118(13):3525-7. doi: 10.1182/blood-2011-03-342485. Epub 2011 Jul 29. Blood. 2011. PMID: 21803850 Free PMC article. Clinical Trial.
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong F, Horning SJ. Smith MR, et al. J Clin Oncol. 2012 Sep 1;30(25):3119-26. doi: 10.1200/JCO.2012.42.2444. Epub 2012 Jul 30. J Clin Oncol. 2012. PMID: 22851557 Free PMC article. Clinical Trial.
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).
Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, Larson RA. Byrd JC, et al. Among authors: smith mr. Blood Adv. 2018 Jul 24;2(14):1705-1718. doi: 10.1182/bloodadvances.2017015396. Blood Adv. 2018. PMID: 30030269 Free PMC article. Clinical Trial.
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: smith mr. Br J Haematol. 2016 May;173(3):404-12. doi: 10.1111/bjh.13975. Epub 2016 Mar 8. Br J Haematol. 2016. PMID: 26953041 Free article.
1,175 results